Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules.
Hickey CM, Digianantonio KM, Zimmermann K, Harbin A, Quinn C, Patel A, Gareiss P, Chapman A, Tiberi B, Dobrodziej J, Corradi J, Cacace AM, Langley DR, Békés M. Hickey CM, et al. Among authors: quinn c. Nat Struct Mol Biol. 2024 Feb;31(2):311-322. doi: 10.1038/s41594-023-01146-w. Epub 2024 Jan 4. Nat Struct Mol Biol. 2024. PMID: 38177675
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J, Ye X, Rousseau E, Januario T, Hamman BD, Rose CM, Cheung TK, Hinkle T, Soto L, Quinn C, Harbin A, Bortolon E, Chen X, Haskell R, Lin E, Yu SF, Del Rosario G, Chan E, Dunlap D, Koeppen H, Martin S, Merchant M, Grimmer M, Broccatelli F, Wang J, Pizzano J, Dragovich PS, Berlin M, Yauch RL. Cantley J, et al. Among authors: quinn c. Nat Commun. 2022 Nov 10;13(1):6814. doi: 10.1038/s41467-022-34562-5. Nat Commun. 2022. PMID: 36357397 Free PMC article.
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
Berlin M, Cantley J, Bookbinder M, Bortolon E, Broccatelli F, Cadelina G, Chan EW, Chen H, Chen X, Cheng Y, Cheung TK, Davenport K, DiNicola D, Gordon D, Hamman BD, Harbin A, Haskell R, He M, Hole AJ, Januario T, Kerry PS, Koenig SG, Li L, Merchant M, Pérez-Dorado I, Pizzano J, Quinn C, Rose CM, Rousseau E, Soto L, Staben LR, Sun H, Tian Q, Wang J, Wang W, Ye CS, Ye X, Zhang P, Zhou Y, Yauch R, Dragovich PS. Berlin M, et al. Among authors: quinn c. J Med Chem. 2024 Jan 25;67(2):1262-1313. doi: 10.1021/acs.jmedchem.3c01781. Epub 2024 Jan 5. J Med Chem. 2024. PMID: 38180485
Impact of randomly assigned "pay-as-you-go" liquefied petroleum gas prices on energy use for cooking: Experimental pilot evidence from rural Rwanda.
Witinok-Huber R, Keller KP, Abimana E, Ahishakiye C, Chang HH, L'Orange C, Manning DT, Mori R, Muhirwa EF, Muhongerwa L, Ntakirutimana T, Puzzolo E, Quinn C, Rosa G, Tanner K, Young BN, Zimmerle D, Kalisa E, Volckens J, Clark ML. Witinok-Huber R, et al. Among authors: quinn c. Energy Sustain Dev. 2024 Jun;80:101455. doi: 10.1016/j.esd.2024.101455. Epub 2024 May 6. Energy Sustain Dev. 2024. PMID: 38799418
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Among authors: quinn c. Lancet Neurol. 2024 May 20:S1474-4422(24)00134-0. doi: 10.1016/S1474-4422(24)00134-0. Online ahead of print. Lancet Neurol. 2024. PMID: 38782015
C9orf72 repeat expansions modify risk for secondary motor and cognitive-behavioral symptoms in behavioral-variant frontotemporal degeneration and amyotrophic lateral sclerosis.
Spencer BE, Xie SX, Elman LB, Quinn CC, Amado D, Baer M, Lee EB, Van Deerlin V, Dratch L, Massimo L, Irwin DJ, McMillan CT. Spencer BE, et al. Among authors: quinn cc. medRxiv [Preprint]. 2024 May 1:2024.04.30.24306638. doi: 10.1101/2024.04.30.24306638. medRxiv. 2024. PMID: 38746326 Free PMC article. Preprint.
A transparent approach: Openness in forensic science reporting.
Ballantyne KN, Summersby S, Pearson JR, Nicol K, Pirie E, Quinn C, Kogios R. Ballantyne KN, et al. Among authors: quinn c. Forensic Sci Int Synerg. 2024 May 4;8:100474. doi: 10.1016/j.fsisyn.2024.100474. eCollection 2024. Forensic Sci Int Synerg. 2024. PMID: 38737993 Free PMC article. Review.
1,589 results